Innovation is the lifeblood of
We are committed to building a brighter future for patients. Using new
discoveries and insights in hematology, we are advancing the frontiers
of biology to create life-changing medicines.
A Focus on Hematology
Disc was founded with a single-minded focus on hematology. Blood is fundamental and runs through every aspect of life. But when blood is affected by disease, it can create suffering that is just as far reaching. From rare genetic disorders to blood cancers to complications of chronic diseases that affect millions, we saw areas of medicine with few options for patients, and to where we are dedicating ourselves to design and develop new therapies for these disorders.
Medicines that Matter
Our vision is to build a company that is geared toward bringing therapies that will matter to patients. In every aspect of our work, from the technology we pursue, to the talented team we have assembled, and to the partners we work with, our priority is taking promising new science and transforming it into something useful – medicines that we hope will heal, cure, and alleviate suffering.
We are a team of talented scientists and industry veterans who have deep experience in bringing therapies from discovery, through development, and ultimately to the patients who need them. Our company believes that we can make an impact through scientific rigor, compassion for one another and unwavering tenacity.
Andeleeb is the Head of Global Regulatory Affairs and brings over 15 years of experience in Regulatory Affairs both in the pharmaceutical and biotechnology sectors. Prior to Disc, she had different roles in the regulatory departments of several companies such as Astellas, Sanofi/Genzyme and Novartis/Sandoz. She was responsible for multiple successful submissions to global health authorities, such as the FDA, EMA, PMDA, and many others. Her expertise extends across the entire product development lifecycle, encompassing early-stage development, late-stage development, and post-approval phases.
Andeleeb was responsible for developing regulatory strategies for drug development across a wide spectrum of therapeutic areas, encompassing both rare orphan diseases and more prevalent common diseases. She has also led the Innovative Medicines Initiative (IMI) project on optimizing R&D of advanced therapy medicinal products (ATMP) in collaboration with other pharma and biotech companies. Prior to her work in Regulatory Affairs, she contributed to drug discovery and R&D, utilizing her background as a pharmacist. Andeleeb holds a master’s degree in Drug Innovation from the University of Utrecht.
Rajiv is the Vice President of CMC and Clinical Supply Chain. He brings over a decade of experience in various aspects of CMC such as process, analytical, formulation and manufacturing across small/large molecules and cell therapies. Prior to Disc, Rajiv held roles of increasing responsibilities at Magenta Therapeutics where he served as the head of technical operations supporting GMP DS and DP manufacturing campaigns for a variety of therapeutic modalities (Peptides, Monoclonal Antibodies, ADCs, and Cell Therapies) in Ph1/2 clinical programs. Before Magenta, Rajiv was the head of Analytical CMC at Eleven Biotherapeutics (later Sesen Bio). At Eleven, Rajiv led CMC activities in support of Ph2/3 clinical programs involving monoclonal antibodies and Fusion proteins. Rajiv started his career at Akrivis Technologies where he led the development of Akrivis’s proprietary technology to target small size tumor lesions and cancer stem cells. His work at Akrivis resulted in multiple NIH/NCI awards.
Rajiv holds a BS in Pharmaceutical Sciences from MD University in India and MS/PhD in Interdisciplinary Pharmaceutical Sciences from Northeastern University in Boston.